These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 24640269)

  • 21. Alternative therapeutic approaches to chronic proton pump inhibitor treatment.
    Fass R
    Clin Gastroenterol Hepatol; 2012 Apr; 10(4):338-45; quiz e39-40. PubMed ID: 22178462
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The appropriateness of a proton pump inhibitor prescription.
    Moran N; Jones E; O'Toole A; Murray F
    Ir Med J; 2014; 107(10):326-7. PubMed ID: 25551900
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Addition of a H2 receptor antagonist to PPI improves acid control and decreases nocturnal acid breakthrough.
    Mainie I; Tutuian R; Castell DO
    J Clin Gastroenterol; 2008 Jul; 42(6):676-9. PubMed ID: 18496394
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patterns of proton pump inhibitor utilization in gastroesophageal reflux disease and the effect of restrictions on reimbursement: a nationwide prescription database study.
    Jonasson C; Tvete IF; Hatlebakk JG
    Scand J Gastroenterol; 2013 Sep; 48(9):1010-7. PubMed ID: 23859491
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potential options to optimize therapy of gastroesophageal reflux disease with proton pump inhibitors.
    Tonini M; Vigneri S; Neri M; Cuomo R; Savarino V; Pace F
    Digestion; 2007; 76(3-4):171-8. PubMed ID: 18046084
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Duodenal ulcer and gastroesophageal reflux disease today: long-term therapy--a sideways glance.
    Bardhan KD
    Yale J Biol Med; 1996; 69(3):211-24. PubMed ID: 9165690
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Practice patterns of reflux medication prescriptions in otolaryngology compared to other specialties.
    Luetzenberg FS; Jiang N
    Laryngoscope; 2020 Feb; 130(2):321-327. PubMed ID: 30861137
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A critical evaluation of proton pump inhibitors in the treatment of gastroesophageal reflux disease.
    Berardi RR
    Am J Manag Care; 2000 May; 6(9 Suppl):S491-505. PubMed ID: 10977489
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neonatal Histamine-2 Receptor Antagonist and Proton Pump Inhibitor Treatment at United States Children's Hospitals.
    Slaughter JL; Stenger MR; Reagan PB; Jadcherla SR
    J Pediatr; 2016 Jul; 174():63-70.e3. PubMed ID: 27131401
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The changing patterns of dispensing branded and generic drugs for the treatment of gastroesophageal reflux disease between 2006 and 2011 in Japan: a retrospective cohort study.
    Murata K; Hinotsu S; Hamada S; Ezoe Y; Muto M; Kawakami K
    BMC Health Serv Res; 2015 Feb; 15():76. PubMed ID: 25885571
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of reflux symptoms with over-the-counter proton pump inhibitors: issues and proposed guidelines.
    Haag S; Andrews JM; Katelaris PH; Gapasin J; Galmiche JP; Hunt R; Layer P; Malfertheiner P; Holtmann G
    Digestion; 2009; 80(4):226-34. PubMed ID: 19844107
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Response of regurgitation to proton pump inhibitor therapy in clinical trials of gastroesophageal reflux disease.
    Kahrilas PJ; Howden CW; Hughes N
    Am J Gastroenterol; 2011 Aug; 106(8):1419-25; quiz 1426. PubMed ID: 21537361
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gastroprotective strategies in chronic NSAID users: a cost-effectiveness analysis comparing single-tablet formulations with individual components.
    de Groot NL; Spiegel BM; van Haalen HG; de Wit NJ; Siersema PD; van Oijen MG
    Value Health; 2013; 16(5):769-77. PubMed ID: 23947970
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The use of acid-decreasing medication in veteran patients with gastro-oesophageal reflux disorder with and without Barrett's oesophagus.
    El-Serag HB; Wieman M; Richardson P
    Aliment Pharmacol Ther; 2008 Jun; 27(12):1293-9. PubMed ID: 18363892
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment patterns and symptom control in patients with GERD: US community-based survey.
    Chey WD; Mody RR; Wu EQ; Chen L; Kothari S; Persson B; Beaulieu N; Lu M
    Curr Med Res Opin; 2009 Aug; 25(8):1869-78. PubMed ID: 19530980
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Review of Histamine-2 Receptor Antagonist and Proton Pump Inhibitor Therapy for Gastroesophageal Reflux Disease in Neonates and Infants.
    Tan J; Jeffries S; Carr R
    Paediatr Drugs; 2023 Sep; 25(5):557-576. PubMed ID: 37458926
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparing proton pump inhibitors with histamin-2 receptor blockers regarding the risk of osteoporotic fractures: a nested case-control study of more than 350,000 Korean patients with GERD and peptic ulcer disease.
    Park JH; Lee J; Yu SY; Jung JH; Han K; Kim DH; Rhee J
    BMC Geriatr; 2020 Oct; 20(1):407. PubMed ID: 33059626
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reducing the cost of proton pump inhibitors by adopting best practice.
    Hughes JD; Tanpurekul W; Keen NC; Ee HC
    Qual Prim Care; 2009; 17(1):15-21. PubMed ID: 19281670
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prescribing proton pump inhibitors for initial treatment of acid-related gastrointestinal diseases in a managed care population.
    Chan J; Hui RL; Szpakowski JL
    Am J Manag Care; 2004 Jul; 10(7 Pt 1):433-41. PubMed ID: 15298365
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gastroprotective drugs in Australia: utilization patterns between 1997 and 2006 in relation to NSAID prescribing.
    Barozzi N; Tett SE
    Clin Ther; 2009 Apr; 31(4):849-61. PubMed ID: 19446158
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.